Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease.

CONCLUSION: MTX treatment of IVIG-resistant KD resulted in rapid defervescence, improvement of clinical symptoms, and normalization of acute-phase reactants in all patients. Thus, MTX could be a candidate treatment for IVIG-resistant KD. PMID: 29214785 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29214785?dopt=Abstract

Source: Yonsei Medical Journal - December 8, 2017 Category: Universities & Medical Training Authors: Jang H, Kim KY, Kim DS Tags: Yonsei Med J Source Type: research

More News: Children | Kawasaki Disease | Methotrexate | Study